1
|
Perrone C, Schilling W, Callery JJ, Ashley EA, Chambers M, Chase H, Dahal P, Kanthawang N, Nedsuwan S, Hanboonkunupakarn B, Intralawan D, Karkey A, Mayxay M, Souvong V, Tran Minh H, Udas Shakya S, Sharma SK, Uranw S, Vannachione S, Woodrow C, White NJ, Cheah PY. Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. Wellcome Open Res 2022; 6:216. [PMID: 36866279 PMCID: PMC9971639 DOI: 10.12688/wellcomeopenres.16880.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/22/2022] [Indexed: 12/02/2022] Open
Abstract
Background: The COPCOV study (chloroquine/ hydroxychloroquine prevention of coronavirus disease), which started recruitment in April 2020, is a multi-country double-blind, randomised, placebo-controlled trial which is being conducted in healthcare facilities involved in COVID-19 case management. Participants are staff employed in facilities managing people with proven or suspected COVID-19. As part of the study, we conducted a series of engagement sessions. The aims were to assess the feasibility of the study, to identify context-specific ethical issues, to understand possible concerns, to fine tune research procedures and to refine the COPCOV information materials. Methods: The COPCOV study was approved by relevant institutional review boards. The sessions described in this paper were part of the study. We conducted a series of engagement sessions, each involving a short presentation of the study, a section where attendees were asked to express their willingness to participate in such a study, which information they would need to change their view and an open Q&A section. Answers were transcribed and coded into themes by two independent investigators. Themes were derived from the data. They complemented other site-specific engagement, communication, and public relation activities such as press releases and websites. Results and conclusions: From 16 th March 2020 to 20 th January 2021, 12 engagement sessions were conducted in Thailand, Laos, Vietnam, Nepal and the UK involving 213 attendees in total. Issues raised revolved around the social value and study rationale; safety of trial medications and risk-benefit balance; study design and commitments. These sessions helped us identify concerns people had, which helped us refine information materials as well as complement site feasibility assessments. Our experience strongly supports the use of participatory practices prior to conducting clinical trials.
Collapse
Affiliation(s)
- Carlo Perrone
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,
| | - William Schilling
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - James J. Callery
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Elizabeth A. Ashley
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
| | - Mary Chambers
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh city, Vietnam
| | - Hannah Chase
- Medical Sciences Divisional Office, University of Oxford, Oxford, UK
| | - Piyush Dahal
- KHDC Program, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | | | - Supalert Nedsuwan
- Primary Care Department, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
| | - Borimas Hanboonkunupakarn
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
| | - Daranee Intralawan
- Primary Care Department, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
| | - Abhilasha Karkey
- Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital,, Kathmandu, Nepal
| | - Mayfong Mayxay
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic,University of Health Sciences in Lao P.D.R., Vientiane, Lao People's Democratic Republic
| | - Vimalay Souvong
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
| | - Hien Tran Minh
- Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh city, Vietnam
| | - Summita Udas Shakya
- Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital,, Kathmandu, Nepal
| | - Sanjib Kumar Sharma
- Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | - Surendra Uranw
- Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | - Souphaphone Vannachione
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
| | - Charles Woodrow
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,John Radcliffe Hospital, Oxford, UK
| | - Nicholas J. White
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Phaik Yeong Cheah
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,The Ethox Centre, University of Exford, Oxford, UK
| |
Collapse
|
2
|
Perrone C, Schilling W, Callery JJ, Ashley EA, Chambers M, Chase H, Dahal P, Kanthawang N, Nedsuwan S, Hanboonkunupakarn B, Intralawan D, Karkey A, Mayxay M, Souvong V, Tran Minh H, Udas Shakya S, Sharma SK, Uranw S, Vannachione S, Woodrow C, White NJ, Cheah PY. Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. Wellcome Open Res 2022; 6:216. [PMID: 36866279 PMCID: PMC9971639 DOI: 10.12688/wellcomeopenres.16880.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/05/2021] [Indexed: 11/20/2022] Open
Abstract
Background: The COPCOV study (chloroquine/ hydroxychloroquine prevention of coronavirus disease), which started recruitment in April 2020, is a multi-country double-blind, randomised, placebo-controlled trial which is being conducted in healthcare facilities involved in coronavirus disease 2019 (COVID-19) case management. COPCOV aims to recruit healthcare workers and other staff employed in facilities managing people with proven or suspected COVID-19. Methods: We conducted a series of engagement sessions, each involving a short presentation of the study, a section where attendees were asked to express if they would be interested in participating in such a study and which information they would need to change their view and an open Q&A section. Answers were transcribed and coded into themes by two independent investigators. Themes were derived from the data. The aims were to assess the feasibility of the study at the respective sites, to identify context-specific ethical issues, to understand concerns potential participants might have, to fine tune research procedures and to refine COPCOV information materials. They complemented other site-specific engagement, communication and public relation activities such as press releases and websites. Results: From 16 th March 2020 to 20 th January 2021, 12 engagement sessions were conducted in Thailand, Laos, Vietnam, Nepal and the UK involving 213 attendees in total. The sessions were designed to encourage potential participants and research professionals not directly involved in the project to interact with those who planned the study and those conducting it. Many attendees were keen to join the study while others had concerns. Questions raised revolved around the social value and study rationale; safety of trial medications and risk-benefit balance; study design and commitments. Conclusions: These sessions helped us refine information materials, identify misunderstandings about the study as well as complement site feasibility assessments. Our experience strongly supports the use of participatory practices prior to conducting clinical trials.
Collapse
Affiliation(s)
- Carlo Perrone
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,
| | - William Schilling
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - James J. Callery
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Elizabeth A. Ashley
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
| | - Mary Chambers
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh city, Vietnam
| | - Hannah Chase
- Medical Sciences Divisional Office, University of Oxford, Oxford, UK
| | - Piyush Dahal
- KHDC Program, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | | | - Supalert Nedsuwan
- Primary Care Department, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
| | - Borimas Hanboonkunupakarn
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
| | - Daranee Intralawan
- Primary Care Department, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
| | - Abhilasha Karkey
- Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital,, Kathmandu, Nepal
| | - Mayfong Mayxay
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic,University of Health Sciences in Lao P.D.R., Vientiane, Lao People's Democratic Republic
| | - Vimalay Souvong
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
| | - Hien Tran Minh
- Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh city, Vietnam
| | - Summita Udas Shakya
- Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital,, Kathmandu, Nepal
| | - Sanjib Kumar Sharma
- Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | - Surendra Uranw
- Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | - Souphaphone Vannachione
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
| | - Charles Woodrow
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,John Radcliffe Hospital, Oxford, UK
| | - Nicholas J. White
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Phaik Yeong Cheah
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,The Ethox Centre, University of Exford, Oxford, UK
| |
Collapse
|
3
|
Perrone C, Schilling W, Callery JJ, Ashley EA, Chambers M, Chase H, Dahal P, Kanthawang N, Nedsuwan S, Hanboonkunupakarn B, Intralawan D, Karkey A, Mayxay M, Souvong V, Tran Minh H, Udas Shakya S, Sharma SK, Uranw S, Vannachione S, Woodrow C, White NJ, Cheah PY. Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. Wellcome Open Res 2022; 6:216. [PMID: 36866279 PMCID: PMC9971639 DOI: 10.12688/wellcomeopenres.16880.2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/17/2021] [Indexed: 12/15/2022] Open
Abstract
Background: The COPCOV study (chloroquine/ hydroxychloroquine prevention of coronavirus disease), which started recruitment in April 2020, is a multi-country double-blind, randomised, placebo-controlled trial which is being conducted in healthcare facilities involved in COVID-19 case management. COPCOV aims to recruit healthcare workers and other staff employed in facilities managing people with proven or suspected COVID-19. Methods: We conducted a series of engagement sessions, each involving a short presentation of the study, a section where attendees were asked to express if they would be interested in participating in such a study and which information they would need to change their view and an open Q&A section. Answers were transcribed and coded into themes by two independent investigators. Themes were derived from the data. The aims were to assess the feasibility of the study at the respective sites, to identify context-specific ethical issues, to understand concerns potential participants might have, to fine tune research procedures and to refine COPCOV information materials. They complemented other site-specific engagement, communication and public relation activities such as press releases and websites. Results: From 16 th March 2020 to 20 th January 2021, 12 engagement sessions were conducted in Thailand, Laos, Vietnam, Nepal and the UK involving 213 attendees in total. The sessions were designed to encourage potential participants and research professionals not directly involved in the project to interact with those who planned the study and those conducting it. Many attendees were keen to join the study while others had concerns. Questions raised revolved around the social value and study rationale; safety of trial medications and risk-benefit balance; study design and commitments. Conclusions: These sessions helped us refine information materials, identify misunderstandings about the study as well as complement site feasibility assessments. Our experience strongly supports the use of participatory practices prior to conducting clinical trials.
Collapse
Affiliation(s)
- Carlo Perrone
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,
| | - William Schilling
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - James J. Callery
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Elizabeth A. Ashley
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
| | - Mary Chambers
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh city, Vietnam
| | - Hannah Chase
- Medical Sciences Divisional Office, University of Oxford, Oxford, UK
| | - Piyush Dahal
- KHDC Program, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | | | - Supalert Nedsuwan
- Primary Care Department, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
| | - Borimas Hanboonkunupakarn
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
| | - Daranee Intralawan
- Primary Care Department, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
| | - Abhilasha Karkey
- Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital,, Kathmandu, Nepal
| | - Mayfong Mayxay
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic,University of Health Sciences in Lao P.D.R., Vientiane, Lao People's Democratic Republic
| | - Vimalay Souvong
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
| | - Hien Tran Minh
- Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh city, Vietnam
| | - Summita Udas Shakya
- Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital,, Kathmandu, Nepal
| | - Sanjib Kumar Sharma
- Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | - Surendra Uranw
- Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | - Souphaphone Vannachione
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
| | - Charles Woodrow
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,John Radcliffe Hospital, Oxford, UK
| | - Nicholas J. White
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Phaik Yeong Cheah
- Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK,The Ethox Centre, University of Exford, Oxford, UK
| |
Collapse
|
4
|
Van Nuil JI, Friska D, Kekalih A, Bhandari AR, Bogh C, Brindle H, Bui THN, Deokota D, Ragil Dien SW, Doan PN, Fisher J, Gautum A, Kurniawan LN, Limato R, Nguyen HY, Nguyen TH, Nguyen TP, Nguyen TT, Nguyen THY, Nguyen TKN, Nguyen TKT, Nguyen Le TM, Pandey A, Rijal S, Roberts C, Shakya R, Shakya SU, Sharma P, Sutrisni IA, Thapa P, Timoria D, Tran MH, Tran PT, Tran TH, Vu BH, Vu TVD, Karkey A, Hamers RL, Chambers M, Lewycka S. COVID-19 Social Science and Public Engagement Action Research in Vietnam, Indonesia and Nepal (SPEAR): Protocol for a mixed methods study exploring the experiences and impacts of COVID-19 for healthcare workers and vulnerable communities. Wellcome Open Res 2021. [DOI: 10.12688/wellcomeopenres.17314.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: When the novel coronavirus – SARS-CoV-2 – started to spread globally, there was a call for social and behavioral scientists to conduct research to explore the wider socio-cultural contexts of coronavirus disease 2019 (COVID-19), to understand vulnerabilities, as well as to increase engagement within communities to facilitate adoption of public health measures. In this manuscript, we describe the protocol for a study conducted in Indonesia, Nepal, and Vietnam. In the study, we explore how the COVID-19 pandemic is affecting individuals and their communities. We focus on the wider health and economic impacts of COVID-19, in particular emerging and increased burden on mental health, as well as new or deepened vulnerabilities in the communities. The introduction of vaccines has added another layer of complexity and highlights differences in acceptance and inequalities around access. Methods: We use mixed methods, combining survey methods and social media surveillance to gain a picture of the general situation within each country, with in-depth qualitative methods to gain a deeper understanding of issues, coupled with a synergistic engagement component. We also include an exploration of the role of social media in revealing or driving perceptions of the pandemic more broadly. Participants include health workers and members of communities from 13 sites across the three countries. Data collection is spread across two phases. Phase 1 is concerned with exploring lived experiences, impacts on working lives and livelihoods, mental health and coping strategies. Phase 2 is concerned with acceptance of COVID-19 vaccines, factors that increase and reduce acceptance, and factors that influence access. Conclusions: We will disseminate findings in multiple ways including short reports and policy briefs, articles in peer-reviewed journals, and digital diaries will be edited into short films and uploaded onto social media sites.
Collapse
|
5
|
Salami O, Horgan P, Moore CE, Giri A, Sserwanga A, Pathak A, Basnyat B, Kiemde F, Smithuis F, Kitutu F, Phutke G, Tinto H, Hopkins H, Kapisi J, Swe MMM, Taneja N, Baiden R, Dutta S, Compaore A, Kaawa-Mafigiri D, Hussein R, Shakya SU, Kukula V, Ongarello S, Tomar A, Chadha SS, Walia K, Kelly-Cirino C, Olliaro P. Impact of a package of diagnostic tools, clinical algorithm, and training and communication on outpatient acute fever case management in low- and middle-income countries: protocol for a randomized controlled trial. Trials 2020; 21:974. [PMID: 33239106 PMCID: PMC7687811 DOI: 10.1186/s13063-020-04897-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Accepted: 11/12/2020] [Indexed: 01/21/2023] Open
Abstract
BACKGROUND The management of acute febrile illnesses places a heavy burden on clinical services in many low- and middle-income countries (LMICs). Bacterial and viral aetiologies of acute fevers are often clinically indistinguishable and, in the absence of diagnostic tests, the 'just-in-case' use of antibiotics by many health workers has become common practice, which has an impact on drug-resistant infections. Our study aims to answer the following question: in patients with undifferentiated febrile illness presenting to outpatient clinics/peripheral health centres in LMICs, can we demonstrate an improvement in clinical outcomes and reduce unnecessary antibiotic prescription over current practice by using a combination of simple, accurate diagnostic tests, clinical algorithms, and training and communication (intervention package)? METHODS We designed a randomized, controlled clinical trial to evaluate the impact of our intervention package on clinical outcomes and antibiotic prescription rates in acute febrile illnesses. Available, point-of-care, pathogen-specific and non-pathogen specific (host markers), rapid diagnostic tests (RDTs) included in the intervention package were selected based on pre-defined criteria. Nine clinical study sites in six countries (Burkina Faso, Ghana, India, Myanmar, Nepal and Uganda), which represent heterogeneous outpatient care settings, were selected. We considered the expected seasonal variations in the incidence of acute febrile illnesses across all the sites by ensuring a recruitment period of 12 months. A master protocol was developed and adapted for country-specific ethical submissions. Diagnostic algorithms and choice of RDTs acknowledged current data on aetiologies of acute febrile illnesses in each country. We included a qualitative evaluation of drivers and/or deterrents of uptake of new diagnostics and antibiotic use for acute febrile illnesses. Sample size estimations were based on historical site data of antibiotic prescription practices for malarial and non-malarial acute fevers. Overall, 9 semi-independent studies will enrol a minimum of 21,876 patients and an aggregate data meta-analysis will be conducted on completion. DISCUSSION This study is expected to generate vital evidence needed to inform policy decisions on the role of rapid diagnostic tests in the clinical management of acute febrile illnesses, with a view to controlling the rise of antimicrobial resistance in LMICs. TRIAL REGISTRATION Clinicaltrials.gov NCT04081051 . Registered on 6 September 2019. Protocol version 1.4 dated 20 December 2019.
Collapse
Affiliation(s)
- Olawale Salami
- Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland
| | - Philip Horgan
- Big Data Institute, University of Oxford, Old Road Campus, Oxford, OX3 7LF UK
| | - Catrin E. Moore
- Big Data Institute, University of Oxford, Old Road Campus, Oxford, OX3 7LF UK
| | - Abhishek Giri
- Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital, Lalitpur, Nepal
| | - Asadu Sserwanga
- Infectious Diseases Research Collaboration (IDRC), Nakasero Hill Rd, Kampala, Uganda
| | - Ashish Pathak
- RD Gardi Medical College, Ujjain, Madhya Pradesh 456001 India
| | - Buddha Basnyat
- Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital, Lalitpur, Nepal
| | - Francois Kiemde
- Institut de Recherche en Sciences de la Santé Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso
| | - Frank Smithuis
- Myanmar Oxford Clinical Research Unit (MOCRU), Yangon, Myanmar
| | - Freddy Kitutu
- Department of Pharmacy, School of Health Sciences, Makerere University, Kampala, Uganda
| | | | - Halidou Tinto
- Institut de Recherche en Sciences de la Santé Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso
| | - Heidi Hopkins
- London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London, WC1E 7HT UK
| | - James Kapisi
- Infectious Diseases Research Collaboration (IDRC), Nakasero Hill Rd, Kampala, Uganda
| | | | - Neelam Taneja
- Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India
| | - Rita Baiden
- Dodowa Health Research Centre, P.O. Box DD1, Dodowa, Ghana
| | - Shanta Dutta
- National Institute of Cholera and Enteric Diseases (NICED), Kolkata, India
| | - Adelaide Compaore
- London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London, WC1E 7HT UK
| | | | - Rashida Hussein
- Myanmar Oxford Clinical Research Unit (MOCRU), Yangon, Myanmar
| | - Summita Udas Shakya
- Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital, Lalitpur, Nepal
| | - Vida Kukula
- Dodowa Health Research Centre, P.O.Box DD1, Dodowa, Ghana
| | - Stefano Ongarello
- Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland
| | - Anjana Tomar
- FIND India, 9th Floor, Vijaya Building, 17, Barakhamba Road, New Delhi, 110001 India
| | - Sarabjit S. Chadha
- FIND India, 9th Floor, Vijaya Building, 17, Barakhamba Road, New Delhi, 110001 India
| | - Kamini Walia
- Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, Ansari Nagar, New Delhi, 110029 India
| | - Cassandra Kelly-Cirino
- Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland
| | - Piero Olliaro
- Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland
| |
Collapse
|